营收情况 - Biogen Inc. (BIIB)在2023年12月结束的季度报告显示，营收为23.9亿美元，同比下降6.2%[1]。 - 报告的营收低于Zacks Consensus Estimate的24.6亿美元，出现-2.88%的意外[2]。 产品营收表现 - 多发性硬化症药物Tysabri在全球其他地区的营收为2.169亿美元，同比增长1.2%[5]。 - Tysabri在美国的营收为2.478亿美元，同比下降9.6%[6]。 - Spinal Muscular Atrophy药物Spinraza在美国的营收为1.575亿美元，同比增长0.4%[8]。 - Contract manufacturing、royalty和其他营收为1.181亿美元，同比下降38.4%[9]。 股票表现 - Biogen Inc.的股票在过去一个月中回报率为-1.4%，表现低于Zacks S&P 500综合指数的+5.1%变化[16]。

Biogen Inc.第四季度财报 - 第四季度每股收益为2.95美元，低于Zacks Consensus Estimate的3.16美元[1] - 第四季度营收为23.9亿美元，低于Zacks Consensus Estimate的2.88%[3] - 股价自年初以来下跌了约5.4%[4] 盈利前景分析 - 公司的盈利前景对股价走势有重要影响[5] - 盈利预期和盈利估计变化对股价走势有显著影响[6] - 未来季度和当前财年的盈利预期分别为每股3.49美元和15.71美元[8] 公司估值和行业前景 - 公司的估值趋势为Zacks Rank 3 (Hold)，预计未来股价将与市场表现持平[7] - 行业前景对公司的股价表现有重要影响[9]

Q4 and Full Year 2023 Financial Results and Business Update Non-GAAP financial information This presentation and the discussions during this conference call include certain financial measures that were not prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), including adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, ...

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. Revenue from multiple sclerosis products fell 8% to $1.17 billion as the therapies face competition from cheaper generics. The results come as the ...

Biogen公司新药SKYCLARYS®获得欧盟授权 - Biogen公司宣布欧洲委员会(EC)已授权SKYCLARYS® (omaveloxolone)用于治疗成年人和16岁及以上青少年的Friedreich氏共济失调(FA)[1] - SKYCLARYS是欧盟内首个获批用于治疗这种罕见的、遗传性、进行性神经退行性疾病的治疗方法[1] - SKYCLARYS在MOXIe第2部分试验中显示出显著改善了接受治疗患者的修改后Friedreich共济失调评分(mFARS)相对于安慰剂组[1] - Biogen致力于与医学界和当地政府合作，以确保患者能够获得这种治疗[1]

We expect Biogen (BIIB) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 13, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.27%. Factors to Consider Biogen’s sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and rising competitive pressure in the MS market. Tecfidera sales have been declining as multiple generic versions of the drug h ...

Wall Street analysts expect Biogen Inc. (BIIB) to post quarterly earnings of $3.16 per share in its upcoming report, which indicates a year-over-year decline of 22%. Revenues are expected to be $2.46 billion, down 3.4% from the year-ago quarter. Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefra ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on February 13, 2024, might help the stock move higher if these key numbers are better tha ...

股价表现 - Biogen Inc. (BIIB) 最新收盘价为 $243.72，较前一日下跌了 1.66% [1] - Biogen Inc. (BIIB) 近一个月股价下跌了 4.78%，落后于医疗行业的涨幅 4.02% 和标普500指数的涨幅 2.93% [2] 财务预测 - Biogen Inc. (BIIB) 即将发布财报，预计每股收益为 $3.16，较去年同期下降了 21.98%，预计营收为 $2.46 亿美元，较去年同期下降了 3.43% [3] - 分析师对 Biogen Inc. (BIIB) 的最新预测调整可能反映了短期业务模式的变化，积极的预测调整可能预示着公司业务前景良好 [4] 股票评级 - Biogen Inc. (BIIB) 目前的 Zacks Rank 为 3 (Hold)，Zacks Consensus EPS 预测在过去30天内下降了 0.16% [6] 估值指标 - Biogen Inc. (BIIB) 目前的前瞻市盈率为 15.75，低于行业平均值 21.16，显示公司目前以折扣价交易 [7] - BIIB 目前的 PEG 比率为 2.7，结合了公司预期的盈利增长率 [8] 行业比较 - 医疗 - 生物医学和遗传学行业的平均 PEG 比率为 1.79 [9] - 医疗 - 生物医学和遗传学行业是医疗行业的一部分，目前该行业的 Zacks Industry Rank 为 96，在所有 250+ 个行业中排名前 39% [10] 行业排名 - Zacks Industry Rank 按照每个行业内公司的平均 Zacks Rank 从好到坏排序，研究显示排名前50%的行业的表现是排名后50%的两倍 [11]

Biogen公司调整药物开发策略 - Biogen宣布重新调整资源，加快新药Leqembi的开发，并停止争议性AD药物Aduhelm的开发和商业化[1][3] - Aduhelm虽然曾被视为潜在的爆款产品，但由于Medicare拒绝覆盖，导致需求降低至最低水平[5] - Biogen计划终止Aduhelm的后市场确认研究，并寻求合作伙伴来分享Aduhelm研究的整体成本[6] - Biogen未能找到Aduhelm研究所需的战略合作伙伴或外部融资，将把Aduhelm的权利归还给Neurimmune，并录得约6000万美元的一次性费用[7] 新药Leqembi的发展和市场前景 - Biogen计划推进新的AD药物Leqembi/lecanemab，该药已获得FDA批准，并在2023年7月获得CMS的广泛报销[9] - 欧洲药品管理局目前正在审查Leqembi的营销申请，Biogen的日本合作伙伴Eisai宣布将举行会议讨论Leqembi的营销授权申请[10] - Biogen与Eisai合作开发Leqembi，Eisai主导临床开发和监管提交，两家公司共同推广该药[11]